GlassScriptPhysician profile
Jeffrey A Golden
NPI 1043267446
$5,720.42
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $5,287 · 2020: $124 · 2021: $112 · 2022: $197.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| F. Hoffmann-La Roche Ag | $2,669.98 | 2019-2022 | |
| Pulmonx Corporation | $2,025.00 | 2019 | |
| Eli Lilly and Company | $500.00 | 2019 | |
| United Therapeutics Corporation | $401.08 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.36 | 2020 |
8 companies reported research payments only; those appear in the research section below.
Research and ownership
$1,710.27 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$1,554.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Golden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.